Pete Stibbs: Advancing Treatment Strategies in Venous Disease
Pete Stibbs, Senior Vice President, Global Medical Affairs and Medical Director at Argon Medical Devices, shared a post on LinkedIn:
“Great discussions on venous disease at VEITH 2026.
I especially enjoyed Jose Almeida’s point-counterpoint session on the treatment of deep and superficial venous disease.
It’s always a pleasure to hear colleagues make a thoughtful case for opposing approaches and explain which data carry the most weight in their practice.
What struck me was how often those views began to converge once the discussion turned to patient selection.
That came through most clearly in the debate over mechanical thrombectomy versus catheter-directed thrombolysis and in the discussion of venous stenting.
When is a stent warranted, and which patients are most likely to benefit?
Wherever you stand on those questions, it’s encouraging to see new randomized trials and more detailed clinical data helping us refine the treatment algorithms we use in practice.
My thanks to Almeida, the presenters, and the panelists for a candid and clinically relevant discussion.”

Stay updated with Hemostasis Today.
-
Nov 19, 2026, 05:31Lance Reed: One Donation, Multiple Lives
-
Nov 19, 2026, 05:20ZPI Silencing as a Novel Non-Factor Therapy for Rare Bleeding Disorders – HITh
-
Nov 19, 2026, 04:48Antiphospholipid Antibodies and Stroke Management – RPTH
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis
-
Nov 18, 2026, 20:55Nasir Jamal: Plasmapheresis – Key Concepts at a Glance
-
Nov 18, 2026, 20:55Tarık Seller: Pulmonary Embolism – When a Blood Clot Becomes a Life-Threatening Emergency
-
Nov 18, 2026, 20:53Sandya Arunachalam: Bringing the Profession Together at the Haemostasis and Thrombosis Workshop
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood